Atai Beckley N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.830
-0.060 (-1.54%)
Dec 1, 2025, 12:46 PM EST - Market open
Atai Beckley Revenue
Atai Beckley had revenue of $749.00K in the quarter ending September 30, 2025, with 1,772.50% growth. This brings the company's revenue in the last twelve months to $3.02M, up 811.78% year-over-year. In the year 2024, Atai Beckley had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$3.02M
Revenue Growth
+811.78%
P/S Ratio
242.20
Revenue / Employee
$55,889
Employees
54
Market Cap
820.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATAI News
- 11 days ago - Enhanced Fortifies Executive Leadership Team & Board of Directors - PRNewsWire
- 20 days ago - Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript - Seeking Alpha
- 5 weeks ago - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - GlobeNewsWire
- 6 weeks ago - Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics - Seeking Alpha
- 6 weeks ago - Why Atai Life Sciences Stock Was So Lively This Week - The Motley Fool
- 6 weeks ago - atai Life Sciences Announces Pricing of Public Offering of Common Shares - GlobeNewsWire
- 6 weeks ago - atai Life Sciences Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 6 weeks ago - atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression - GlobeNewsWire